BioNTech's Vision and Strategy - BioNTech aims to build a global immunotherapy powerhouse translating science into survival[13] - BioNTech has distributed 5 billion doses of COVID-19 vaccine globally[12] - BioNTech is leveraging AI to pioneer personalized immunotherapies[62] InstaDeep's AI Capabilities and Technologies - InstaDeep's AI supercomputer, Kyber, has ~500 PetaFLOPS of Nvidia H100 GPUs and 86,000 CPU Cores[105] - InstaDeep's AI training platform, AIChor, has seen +15,000 experiments per month in 2025 with +75% GPU usage[109] - Nucleotide Transformer (NTv3) pre-trained on genomes from >150,000 species and post-trained on >17,000 functional tracks across 16 species[154] AI-Driven Innovation in Genomics and Proteomics - InstaNovo V2 achieves up to 2x the number of identifications in peptide sequencing[263] - AI-assisted tissue annotation tool increased pathologist efficiency fivefold (5x)[265] - AI pipeline achieves an average 50,000-fold TCR binding enhancement increase over WT[345]

BioNTech (BNTX) Q4 2024 Earnings Call March 10, 2025 08:17 PM ET Company Participants Michael Horowicz - Director - IRUgur Sahin - Co-Founder, CEO & Chair of the Management BoardÖzlem Türeci - Co-Founder, Chief Medical Officer & Member of Management BoardJens Holstein - CFORyan Richardson - Chief Strategy OfficerAkash Tewari - Managing DirectorTazeen Ahmad - MD - US Equity ResearchHarry Gillis - Vice President - Pharmaceuticals Equity ResearchCory Kasimov - Senior Managing Director Conference Call Participa ...